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Location of metastases in cancer of 
unknown primary are not random 
and signal familial clustering
Kari Hemminki1,2, Kristina Sundquist2,3, Jan Sundquist2,3, Akseli Hemminki4,5 & Jianguang Ji2
Cancer of unknown primary (CUP) is a fatal disease diagnosed through metastases. It shows intriguing 
familial clustering with certain defined primary cancers. Here we examine whether metastatic location 
in CUP patients is related to primary non-CUP cancers in relatives based on the Swedish Cancer Registry. 
Standardized incidence ratios (SIRs) were calculated for CUP patients defined by metastatic location 
depending on cancer in their first degree relatives. SIRs for CUP were high in association with liver 
(3.94), ovarian (3.41), lung (2.43) and colorectal cancers (1.83) in relatives. The SIR was 1.63 for CUP 
with metastases in the abdomen when a relative was diagnosed with ovarian cancer. CUP with liver 
metastases associated with liver (1.44) cancer in relatives. CUP with head and neck region metastases 
associated with relatives’ esophageal (2.87) cancer. CUP metastases in the thorax associated with 
a relative’s cancers in the upper aerodigestive tract (2.14) and lung (1.74). The findings, matching 
metastatic location in CUP and primary cancer in relatives, could be reconciled if these cases of CUP 
constitute a phenotypically modified primary lacking tissue identification, resulting from epitope 
immunoediting. Alternatively, CUP metastases arise in a genetically favored tissue environment (soil) 
promoting growth of both primary cancers and metastases (seeds).
In cancer of unknown primary (CUP) the primary site remains unidentified and it has been suggested to be a syn-
drome with specific clinical characteristics featuring aggressive growth1–3. Recommended diagnostic approaches 
to identify the primary site include detailed histopathological examination with specific immunohistochemis-
try (IHC) and comprehensive radiological assessment with computed tomography scan of the thorax, abdo-
men, and pelvis4. Improved diagnostic tools and evolving molecular methods of tissue-of-origin identification 
increase the likelihood of finding the hidden primary tumor, probably contributing to a decrease in CUP inci-
dence5,6. Although it can be proposed that the frequency of CUP diagnosis is impacted by the breadth and depth 
of the diagnostic arsenal employed, there seems to be a subgroup of tumor metastases which lack any clues with 
regard to tissue of origin even subsequent to profound investigation5–7. In the Nordic countries, CUP incidence 
increased until 1995–2000, followed by a sharp continued decline8,9. In the USA the decline started already in 
around 198010. These patterns are compatible with an initial increase in the capacity for sensitive diagnosis of 
tumor metastases (by computer tomography) and a subsequent increase in the ability of pathologists to specifi-
cally define tissue of origin (by immunohistochemistry)7,11. In spite of the declining incidence, CUP accounts for 
2–4% of all cancers8–10. CUP has a dismal prognosis and it thus ranks the third or fourth among cancer deaths10,12. 
In Sweden, the median survival for CUP overall and for the common histologies, adenocarcinoma and undiffer-
entiated carcinoma, was 3 months13,14. Even though the diagnostics of CUP have improved over time the survival 
has remained largely unchanged and worst for all cancers over many decades, suggesting that the disease entity 
has remained uniform9,14.
The natural history and pathobiology of CUP are poorly understood, chiefly because of the elusive nature of 
the primary tumor, which precludes evidence-based treatment, compounded by rapid metastatic spread to mul-
tiple organs, a feature compatible with escape variants lacking any immunological control1,3,15,16. Epithelial–mes-
enchymal transition (EMT) is believed to be a pivotal process in the metastatic cascade enabling epithelial cell to 
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irreversibly lose cell to cell contacts and acquiring mesenchymal characteristics17,18. Another process which may 
destroy cellular features recognized by the IHC arsenal used in tissue identification could be immunoediting19,20. 
The immune system is capable of eradicating tumor clones and editing out immunogenic features. The edited 
clones are therefore poorly immunogenic or even immune suppressive (‘stealth clones’), enabling rapid expansion 
characteristics such as seen in many CUP cases11. So far genetic studies on CUP have not revealed germline vari-
ants that would predispose to this cancer16. However, our previous family study showed strong evidence that CUP 
is not a random condition but the risk associates with defined primary cancers in family members2. Thus CUP 
was found in excess in patients whose family members were diagnosed with either CUP or with lung, liver, kidney 
and other cancers. The cause of death in CUP patients was frequently assigned to the fatal organ metastasis, and, 
curiously, CUP patients died often from metastases in the lungs, liver, kidneys or other organs when their relatives 
were diagnosed with primary cancers at the same sites11. We speculated that the results could imply shared genetic 
mechanisms between certain primary cancers and CUP. The rapidly increasing understanding of the interplay 
of the immune system and carcinogenesis supports the alternative or complementary hypothesis that CUP in a 
certain organ may in fact be a an immunologically edited version of a tumor arising from the same organ. Shared 
environmental risk factors could be contributing to these findings but smoking is so far the only established risk 
factor and in fact the magnitude of its effect is much weaker than in lung cancer21,22.
In the present study we wanted to examine the familial associations of CUP using the recently updated 
Swedish Family-Cancer Database with 56,049 patients with CUP diagnosis. Special focus was applied to familial 
risks between primary cancer and CUP with defined metastatic locations. The hypothesis was that if the met-
astatic location matched the primary site in a family member, CUP could in these cases be a phenotypically 
(eg. immunologically) modified primary cancer, redefining the “U” of what used to be CUP. In essence we pro-
pose that CUP diagnosis reflects some degree of deficiency in the usual tissue typing tools (antibodies) to identify 
immunological escape variants. This is not illogical, given that the mentioned antibodies probably recognize the 
very epitopes likely to be immunoedited in escape variants.
Results
In total, 5506 offspring with CUP had a first-degree relative with some cancer with an overall SIR of 1.05 (Table 1). 
As a total of 9171 offspring were diagnosed with CUP, 60% had a relative with any cancer. Cancer sites were 
Cancer in relatives
Parental only Sibling only Parent and sibling First degree relatives
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI
Upper aerodigestive tract 146 1.33 1.12 1.56 58 1.12 0.85 1.44 2 1.94 0.18 7.13 206 1.26 1.10 1.45
Esophagus 52 1.28 0.95 1.68 23 1.28 0.81 1.92 1 7.22 0.00 41.39 76 1.29 1.02 1.62
Stomach 239 0.96 0.84 1.09 44 1.13 0.82 1.51 3 1.31 0.25 3.87 286 0.98 0.87 1.10
Colorectum 564 0.96 0.88 1.04 237 1.12 0.98 1.26 24 1.83 1.17 2.63 825 1.01 0.95 1.08
Colon 347 0.92 0.83 1.02 134 1.03 0.87 1.23 18 1.78 1.05 2.81 499 0.97 0.88 1.05
Rectum 217 1.02 0.89 1.16 103 1.25 1.02 1.51 6 1.98 0.71 4.35 326 1.09 0.98 1.22
Liver 177 1.14 0.98 1.33 54 1.40 1.05 1.83 4 3.94 1.03 10.19 235 1.21 1.06 1.38
Pancreas 152 1.01 0.85 1.18 54 1.19 0.90 1.56 4 2.87 0.75 7.42 210 1.06 0.92 1.22
Lung 404 1.19 1.07 1.31 284 1.71 1.52 1.92 25 2.43 1.57 3.59 713 1.38 1.28 1.48
Breast 484 1.00 0.91 1.10 435 1.17 1.06 1.29 35 1.10 0.77 1.53 954 1.08 1.01 1.15
Cervix 103 1.09 0.89 1.33 44 1.09 0.79 1.46 0 147 1.09 0.92 1.28
Endometrium 125 0.96 0.80 1.15 68 0.99 0.77 1.26 2 1.10 0.10 4.04 195 0.97 0.84 1.12
Ovary 121 1.12 0.93 1.34 62 1.07 0.82 1.37 5 3.41 1.08 8.03 188 1.12 0.97 1.30
Prostate 706 1.05 0.98 1.13 361 1.07 0.96 1.19 48 0.91 0.67 1.21 1115 1.05 0.99 1.12
Kidney 171 1.11 0.95 1.29 69 1.22 0.95 1.54 3 1.96 0.37 5.81 243 1.14 1.00 1.30
Urinary bladder 264 1.12 0.99 1.26 104 1.14 0.93 1.39 3 0.75 0.14 2.21 371 1.12 1.01 1.24
Melanoma 114 1.11 0.92 1.33 126 1.08 0.90 1.28 4 1.43 0.37 3.70 244 1.10 0.96 1.24
Skin, squamous cell 209 0.96 0.83 1.10 69 1.04 0.81 1.32 3 0.91 0.17 2.68 281 0.98 0.87 1.10
Nervous system 127 1.08 0.90 1.29 95 1.03 0.83 1.26 1 0.52 0.00 3.01 223 1.05 0.92 1.20
Thyroid gland 42 1.24 0.90 1.68 24 1.02 0.65 1.52 0 66 1.15 0.89 1.46
Endocrine glands 76 1.06 0.83 1.32 54 1.10 0.83 1.44 1 1.36 0.00 7.80 131 1.08 0.90 1.28
Connective tissue 29 0.97 0.65 1.39 31 1.91 1.30 2.71 1 11.33 0.00 64.92 61 1.32 1.01 1.69
Non-Hodgkin lymphoma 185 1.00 0.86 1.16 104 1.05 0.86 1.28 2 0.54 0.05 1.98 291 1.01 0.90 1.14
Myeloma 85 1.10 0.88 1.36 25 0.90 0.58 1.33 1 1.62 0.00 9.27 111 1.05 0.86 1.27
Leukemia 95 1.08 0.87 1.32 44 1.04 0.76 1.40 0 139 1.06 0.89 1.26
CUP 189 1.07 0.93 1.24 85 1.40 1.12 1.73 0 274 1.15 1.02 1.30
All 3188 0.99 0.96 1.03 1133 1.09 1.02 1.15 172 1.24 1.06 1.43 5506 1.05 1.02 1.08
Table 1.  Risk of cancer of unknown primary for offspring with first degree relatives diagnosed with cancer. 
O = observed number of cases in offspring. Bolding shows that the 95% confidence limits (95%CI) do not 
include 1.00.
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included in the Tables when at least 50 cases were found for ‘First degree relatives’; yet the bottom line ‘All’ 
includes all cancer sites. The overall SIR was not increased (0.99) when a parent was diagnosed with any cancer, 
for siblings the SIR was 1.09, and for offspring when a parent and a sibling were affected it was 1.24. For concord-
ant CUP, only the risk between siblings was increased (1.40). Offspring CUP was associated with 2 discordant 
cancer sites in parents, 6 discordant cancers among siblings and 4 cancers (counting colon and colorectum as 
one) in parents and siblings. Among siblings, high SIRs were found for CUP and connective tissue tumors (1.91) 
and CUP and lung cancer (1.71). For multiplex families (parent and offspring affected) CUP associated with liver 
(3.94), ovarian (3.41), lung (2.43) and colorectal cancers (1.83). None of the multiplex families had more than 3 
affected individuals, i.e., offspring with CUP and a sibling and a parent with cancer X; thus no extensive pedigrees 
were available. The median age of onset of CUP in the offspring generation was 59 years and it was unchanged in 
familial pairs of significant risk in Table 1.
As the incidence of CUP has changed over time it would be relevant to consider possible periodic changes in 
familial risk. However, a proper analysis is difficult because parents and offspring belong to different generations 
with different background rates for CUP and different age constrains (cf. Methods). Offspring risk of CUP (parent 
diagnosed with CUP) was practically unchanged whether the diagnosis was before year 2000 (1.06) or later (1.08, 
both SIRs non-significant).
The analyses in reverse order, i.e., risk of cancer in offspring when a relative was diagnosed with CUP are 
shown in Table 2. The SIRs were increased for 12 cancers when parents were diagnosed with CUP. The risks were 
highest for ovarian (1.30), liver (1.28) and colon cancers (1.26). The risks between siblings were not completely 
independent from Table 1 because the affected sibling pairs were identical but person-years at risk differed. New 
associations compared to Table 1, colorectal (and colon), pancreatic, prostate and kidney cancers associated with 
CUP. The SIR was 2.36 for lung cancer when a parent and a sibling were diagnosed with CUP. There were no 
deviations in ages of onset in familial cases compared non-familial cases.
In Table 3 risks of CUP in offspring with extranodal metastases are shown depending on the location of metas-
tases and cancers in first degree relatives. For all extranodal metastases, concordant CUP and 6 discordant can-
cers associated. For simplicity, only sites with some significant associations were shown. When CUP metastases 
were found in the abdomen, the SIR was 1.63 when a relative was diagnosed with ovarian cancer and it was 1.29 
when a relative was diagnosed with stomach cancer. CUP with liver metastases associated with liver (1.44), lung 
(1.41) and breast (1.19) cancers in relatives. For CUP with head and neck metastases the only associations were 
Cancer in offspring
Parental only Sibling only Parent and sibling First degree relatives
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI
Upper aerodigestive tract 188 1.18 1.02 1.36 59 1.15 0.88 1.49 1 0.95 0.00 5.45 248 1.17 1.03 1.33
Esophagus 61 1.15 0.88 1.47 25 1.33 0.86 1.96 0 86 1.19 0.95 1.47
Stomach 97 0.97 0.79 1.19 46 1.33 0.97 1.78 0 143 1.06 0.89 1.25
Colorectum 754 1.23 1.14 1.32 270 1.27 1.12 1.43 7 1.60 0.63 3.00 1031 1.24 1.17 1.32
Colon 479 1.26 1.15 1.38 162 1.23 1.05 1.44 4 1.47 0.38 3.80 645 1.25 1.16 1.36
Rectum 275 1.18 1.05 1.33 108 1.34 1.10 1.62 3 1.80 0.34 5.32 386 1.23 1.11 1.35
Liver 136 1.28 1.08 1.52 55 1.48 1.11 1.93 1 1.31 0.00 7.51 192 1.33 1.15 1.54
Pancreas 151 1.25 1.06 1.47 62 1.45 1.11 1.86 0 213 1.30 1.13 1.48
Lung 542 1.22 1.12 1.33 305 1.91 1.70 2.13 8 2.36 1.01 4.67 855 1.41 1.32 1.51
Breast 1487 1.11 1.06 1.17 505 1.24 1.13 1.35 9 1.01 0.46 1.92 2001 1.14 1.09 1.19
Cervix 160 1.08 0.92 1.26 47 1.19 0.88 1.59 0 207 1.10 0.95 1.26
Endometrium 226 1.07 0.94 1.22 69 0.90 0.70 1.14 3 1.81 0.34 5.37 298 1.03 0.92 1.15
Ovary 227 1.30 1.13 1.48 69 1.22 0.95 1.55 0 296 1.27 1.13 1.43
Prostate 1270 1.19 1.12 1.25 456 1.21 1.11 1.33 7 0.89 0.35 1.83 1733 1.19 1.14 1.25
Kidney 186 1.14 0.99 1.32 72 1.31 1.02 1.65 0 258 1.18 1.04 1.33
Urinary bladder 296 1.18 1.05 1.33 101 1.14 0.93 1.39 4 2.21 0.57 5.71 401 1.18 1.07 1.30
Melanoma 525 1.13 1.04 1.23 133 1.05 0.88 1.24 4 1.49 0.39 3.84 662 1.12 1.03 1.20
Skin, squamous cell 211 1.02 0.89 1.17 66 0.94 0.73 1.20 3 2.10 0.40 6.21 280 1.01 0.89 1.13
Nervous system 334 0.99 0.89 1.11 100 1.10 0.90 1.34 1 0.52 0.00 2.99 435 1.01 0.92 1.11
Thyroid gland 104 1.24 1.01 1.50 25 1.11 0.72 1.64 0 129 1.20 1.00 1.43
Endocrine glands 182 1.09 0.94 1.26 58 1.16 0.88 1.50 1 0.93 0.00 5.32 241 1.11 0.97 1.25
Connective tissue 70 1.26 0.98 1.59 29 1.87 1.25 2.69 1 3.14 0.00 17.98 100 1.40 1.14 1.70
Non-Hodgkin lymphoma 337 1.11 0.99 1.23 110 1.12 0.92 1.35 0 447 1.10 1.00 1.21
Myeloma 90 1.18 0.95 1.45 27 1.04 0.69 1.52 0 117 1.14 0.94 1.37
Leukemia 160 1.05 0.90 1.23 42 1.05 0.76 1.42 0 202 1.05 0.91 1.20
CUP 189 1.12 0.97 1.29 85 1.45 1.16 1.79 0 274 1.20 1.06 1.35
All 8342 1.14 1.12 1.17 2903 1.24 1.20 1.29 52 1.05 0.79 1.38 11297 1.17 1.15 1.19
Table 2.  Risk of cancer in offspring with first degree relatives diagnosed with CUP. O = observed number of 
cases in offspring. Bolding shows that the 95% confidence limits (95%CI) do not include 1.00.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:22891 | DOI: 10.1038/srep22891
to relatives’ esophageal (2.87) and lung (1.77) cancers. Metastases in the thorax associated with a relative’s CUP 
(1.93) and cancers in the upper aerodigestive tract (2.14) and lung (1.74).
Cancer risks in offspring are shown by location of CUP metastases in relatives in Table 4. Note that in order 
to make the results completely independent from those in Table 3, only parental CUP was considered. When 
relatives had any extranodal metastases, 7 cancers were increased in offspring, including kidney and nervous 
system cancers as novel sites. Ovarian cancer was increased to 1.77 or 1.64 when a parent was diagnosed with 
abdominal or liver CUP, respectively. Prostate and colon cancer associated also with parental liver cancer. Upper 
aerodigestive tract cancer was increased to 2.56 and kidney cancer to 2.90 when a parent was diagnosed with head 
and neck metastases. Endometrial (1.89) and prostate (1.51) cancers were in excess when parents presented with 
thorax metastases.
CUP is diagnosed in various histological types (cf. Methods) and we tested whether there might be histologi-
cal concordance in 2 family members, one presenting with CUP and the other with lung cancer, or one with CUP 
of melanoma histology and the other with melanoma (Table 5). For offspring CUP of squamous cell histology the 
Cancer in relatives
All Abdomen Liver Head & neck Thorax
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI
Upper aerodigestive tract 171 1.25 1.07 1.45 40 1.29 0.92 1.75 33 1.22 0.84 1.71 7 0.91 0.36 1.88 15 2.14 1.19 3.54
Esophagus 57 1.15 0.87 1.49 15 1.34 0.75 2.21 9 0.92 0.42 1.75 8 2.87 1.22 5.68 4 1.58 0.41 4.08
Stomach 248 1.00 0.88 1.13 72 1.29 1.01 1.63 42 0.88 0.63 1.18 15 1.17 0.65 1.94 14 1.16 0.63 1.95
Colorectum 691 1.00 0.93 1.08 164 1.05 0.89 1.21 146 1.09 0.92 1.27 30 0.79 0.53 1.10 34 1.00 0.69 1.36
Colon 418 0.96 0.87 1.06 102 1.03 0.84 1.25 92 1.08 0.87 1.32 14 0.58 0.32 0.98 19 0.88 0.53 1.37
Rectum 273 1.08 0.96 1.22 62 1.08 0.83 1.39 54 1.10 0.83 1.44 16 1.16 0.66 1.89 15 1.20 0.67 1.99
Liver 187 1.14 0.98 1.31 45 1.21 0.88 1.62 46 1.44 1.05 1.92 13 1.47 0.78 2.52 6 0.74 0.27 1.62
Lung 603 1.39 1.28 1.51 113 1.15 0.95 1.39 121 1.41 1.17 1.68 44 1.77 1.29 2.38 39 1.74 1.24 2.38
Breast 805 1.08 1.01 1.16 195 1.15 1.00 1.33 172 1.19 1.02 1.38 51 1.23 0.92 1.62 37 1.00 0.70 1.38
Endometrium 166 0.98 0.84 1.15 44 1.15 0.84 1.55 33 1.01 0.70 1.42 10 1.08 0.52 2.00 9 1.11 0.50 2.11
Ovary 167 1.18 1.01 1.38 52 1.63 1.22 2.14 36 1.31 0.92 1.82 10 1.30 0.62 2.39 3 0.43 0.08 1.27
Prostate 957 1.07 1.01 1.14 223 1.10 0.96 1.25 180 1.04 0.90 1.21 57 1.17 0.89 1.52 36 0.82 0.57 1.14
Kidney 206 1.15 1.00 1.31 46 1.13 0.83 1.51 37 1.07 0.75 1.47 14 1.45 0.79 2.44 7 0.80 0.32 1.66
Urinary bladder 317 1.14 1.02 1.27 66 1.04 0.81 1.33 54 0.99 0.74 1.29 18 1.15 0.68 1.82 20 1.43 0.87 2.21
Nervous system 186 1.05 0.90 1.21 45 1.12 0.81 1.50 39 1.14 0.81 1.56 9 0.92 0.42 1.76 12 1.38 0.71 2.42
CUP 236 1.17 1.03 1.33 53 1.17 0.87 1.53 45 1.16 0.84 1.55 7 0.64 0.25 1.33 19 1.93 1.16 3.02
All 4635 1.05 1.02 1.08 1062 1.06 1.00 1.12 903 1.05 0.99 1.12 269 1.10 0.98 1.24 227 1.04 0.91 1.18
Table 3.  Risk of cancer of unknown primary with defined extranodal metastases for offspring with first 
degree relatives diagnosed with cancer.
Cancer
All Abdomen Liver Head & neck Thorax
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI
Upper aerodigestive tract 95 1.13 0.91 1.38 20 0.93 0.57 1.44 13 0.72 0.38 1.23 7 2.56 1.02 5.31 8 1.10 0.47 2.17
Esophagus 30 1.08 0.73 1.55 5 0.71 0.22 1.66 8 1.36 0.58 2.68 2 2.41 0.23 8.85 3 1.26 0.24 3.74
Stomach 34 0.67 0.46 0.94 6 0.47 0.17 1.02 8 0.76 0.32 1.50 0 2 0.49 0.05 1.80
Colorectum 375 1.24 1.12 1.37 90 1.16 0.94 1.42 82 1.30 1.03 1.60 10 1.10 0.53 1.89 34 1.37 0.95 1.87
 Colon 236 1.28 1.12 1.45 59 1.25 0.95 1.62 52 1.35 1.01 1.77 8 1.44 0.61 2.85 20 1.33 0.81 2.05
 Rectum 139 1.18 0.99 1.39 31 1.03 0.70 1.47 30 1.22 0.82 1.74 2 0.57 0.05 2.08 14 1.44 0.78 2.42
Liver 58 1.08 0.82 1.40 10 0.73 0.35 1.35 15 1.33 0.74 2.21 3 1.84 0.35 5.44 7 1.56 0.62 3.23
Lung 287 1.28 1.13 1.43 80 1.39 1.10 1.73 52 1.10 0.82 1.44 10 1.51 0.72 2.80 21 1.08 0.67 1.65
Breast 786 1.08 1.01 1.16 207 1.12 0.97 1.28 165 1.08 0.92 1.26 23 1.00 0.63 1.50 63 1.06 0.81 1.36
Endometrium 120 1.15 0.96 1.38 21 0.79 0.49 1.21 21 0.98 0.61 1.50 6 2.11 0.76 4.63 16 1.89 1.08 3.08
Ovary 106 1.24 1.02 1.51 38 1.77 1.25 2.43 29 1.64 1.10 2.36 2 0.77 0.07 2.84 10 1.47 0.70 2.71
Prostate 636 1.20 1.11 1.30 162 1.18 1.01 1.38 138 1.24 1.04 1.47 22 1.43 0.89 2.16 69 1.51 1.18 1.91
Kidney 101 1.27 1.03 1.54 25 1.24 0.80 1.83 18 1.08 0.64 1.71 7 2.90 1.15 6.02 8 1.24 0.53 2.45
Urinary bladder 130 1.08 0.90 1.28 31 1.01 0.68 1.43 27 1.06 0.70 1.55 5 1.39 0.44 3.27 11 1.08 0.53 1.93
Nervous system 192 1.16 1.00 1.33 51 1.24 0.92 1.63 46 1.33 0.97 1.77 7 1.21 0.48 2.52 12 0.95 0.49 1.66
CUP 92 1.06 0.86 1.31 15 0.68 0.38 1.13 19 1.05 0.63 1.64 5 1.94 0.61 4.57 10 1.41 0.67 2.61
All 4210 1.14 1.11 1.18 1044 1.12 1.05 1.19 873 1.13 1.06 1.21 153 1.31 1.11 1.54 368 1.22 1.10 1.35
Table 4.  Risk of cancer in offspring with parents diagnosed with cancer of unknown primary with defined 
extranodal metastases.
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SIR was 1.29 when a parent was diagnosed with lung cancer of the same histology. For adenocarcinoma histology 
the SIR for CUP was 1.67 by sibling lung adenocarcinoma. For CUP with melanoma histology the SIRs were 2.15 
and 2.14 when a parent of a sibling were diagnosed with melanoma.
Discussion
We found an intriguing clustering of CUP with many primary cancers in the context of defined families2. We 
found not only familial clustering but also association of metastatic location with the affected organ system in 
the family member. Salient examples were high risk of offspring abdominal metastatic CUP when relatives were 
diagnosed with ovarian and stomach cancers, CUP with liver metastases when relatives were diagnosed with 
liver cancer, CUP with head and neck region metastases when relatives were diagnosed with esophageal cancer 
and CUP with thorax metastases when relatives were diagnosed with lung cancer. Ovarian cancer association 
was strong also in the reverse analysis, i.e., ovarian cancer risk in offspring by parental metastatic location in the 
abdomen. Even stronger was the association of offspring upper aerodigestive tract cancer with parental head and 
neck metastases. Some additional associations were logical when considering well appreciated metastatic pat-
terns, for example, offspring CUP liver metastases relating to relatives’ lung and breast cancers or offspring liver 
CUP metastases relating to parental prostate and colon cancers23,24. Some significant associations initially seemed 
less obvious. For example, offspring thorax metastases associated with parental endometrial cancer. However, in 
a large autopsy series, the lung was the most common extranodal metastatic site from uterine cancer23.
The possible concordance in histology is another interesting question. However, based on the cancer registry 
data most cancers are adenocarcinomas without further specification. Lung cancer is an exception as several his-
tological types are recorded and the case numbers allow a detailed analysis. We showed here that there was con-
cordance for histology between family members diagnosed with CUP and lung cancer. The risk of CUP was 1.11 
(not significant) in offspring whose parents were diagnosed with melanoma (Table 2) but the risk was increased 
to 2.15 when CUP of rare melanoma histology was considered (Table 5).
The strength of the associations of site specific CUP metastasis and matching site specific primary cancer 
reached up to the level of familial associations between concordant primary cancers which usually show SIRs of 
around 2.025. This is remarkable because of the incidence changes in CUP over the several decades covered in the 
study and most likely affecting parent-offspring comparisons where the periodic difference in diagnoses of the 
two generations may span decades. Furthermore, there may some inconsistencies in diagnosis and reporting of 
metastatic sites in CUP, particularly in moribund patients. The present kind of ‘agnostic’ studies typically apply 
multiple comparisons whereby some associations are likely to be false positives. Thus the consistency of the two 
reversed ways of analysis increases credibility of the findings. But how can we explain these results?
One possible explanation to the findings could be shared risk factors but so far only smoking has been con-
sistently associated with the risk of CUP, and only mainly with CUP with lung metastases21,22. We know from 
previous experience that concordant cancers have a familial risk of about 2.0 between first-degree relatives while 
discordant associations, if any, tend to reach SIRs no higher than 1.1 and 1.2, implying the genes underlying 
familial cancer have site-specific manifestations26. Thus there would be good reasons to assume that some genetic 
factors result in shared predisposition or a fertile ‘soil’ to both a defined primary and CUP metastasis, represent-
ing the ‘seed’27.
The simplest explanation to the findings would be that in fact the ‘hidden primary’ resides in the organ site 
marked by familial cancer, and due to immunoediting or other types of phenotypic plasticity it cannot be rec-
ognized as originating from that organ28. Some support to this hypothesis comes from the implicated primary 
cancers: lung, ovarian, liver and colorectal cancers which do metastasize to distant organs but are also charac-
terized by extensive local growth with fatal consequences29–31. One could even propose that CUP could stand for 
“Cancer Undefinable by modern immunoPathology’’ (because of lack of tissue determining epitopes), in addition 
to the conventional definition. Of course, this is about to change because of the increasing diagnostic application 
of non-IHC based tissue-of-origin methods relying on molecular genetic and gene expression signatures32–34. 
A second theory could invoke the soil part of the common ‘seed and soil’ paradigm27. Accordingly, the genetic 
constitution fosters a favorable environment both to cancer initiation (relative’s primary cancer) and to meta-
static seeding (offspring CUP). The common denominator to these theories could be genetic predisposition to 
faltering immune surveillance which would be permissive to both the growth of primary tumors and seeding of 
metastases.
In Table 1 we saw that CUP risk is quite high in ‘multiplex’ families in which a parent and a sibling were 
diagnosed with the same cancer. E.g. CUP risk was 2.43 when the two other family members were diagnosed 
with lung cancer. Interestingly, this is equally high as the risk for lung cancer when two family members were 
diagnosed with lung cancer (SIR 2.46, Frank et al. unpublished). These data suggest that CUP is reinforcing 
familial risk as if it were a concordant cancer, with implications about the phenotypic modification of the original 
cell type. For colorectal (SIR 1.83 in multiplex families), liver (3.94), lung (2.43) and ovarian (3.41) cancers CUP 
Parental history Sibling history
Lung squamous cell 73 1.29 1.01 1.63 4 1.90 0.49 4.92
Lung adenocarcinoma 41 1.12 0.81 1.53 62 1.67 1.28 2.15
Melanoma 21 2.15 1.33 3.29 19 2.14 1.29 3.35
Table 5.  Risk of cancer of unknown primary of specific histology when a parent or a sibling was diagnosed 
with lung cancer or melanoma with a matching histology.
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may imply a rare high-risk phenotype and may offer a signal to the oncologist taking a family history. It was also 
remarkable that a high percentage of 60% of offspring with CUP had a family member with some cancer.
The relative risks reported in this paper are approximately in the range of concordant primary cancers, such 
as breast, prostate, lung and colorectal cancers35. However, relative risk is not a tangible measure for an individ-
ual and thus clinical genetic counseling prefers absolute risks which consider disease prevalence. In Sweden the 
cumulative incidence of CUP by age 75 is 0.75%, slightly higher than those for pancreatic or kidney cancers36. 
Thus a SIR of 1.45 for a sibling of a CUP patient would translate to an absolute risk of 1.1%, or an extra risk of 
0.35% units. The cumulative risk by age 75 for all cancer is 29.5% in Sweden36.
In summary, although CUP has been considered a heterogeneous syndrome it shows remarkable 
non-randomness with regard to familial risks of many primary cancers. CUP is a component cancer in relatively 
high-risk clusters involving colorectal, liver, lung and ovarian cancers. We speculate that the findings related 
to familial clustering could be reconciled by two non-mutually exclusive phenomena: a) many cases of CUP 
may constitute a phenotypically modified primary cancer which cannot be identified as such because modern 
pathology relies heavily on IHC, which in turn depends on tissue epitopes being present. If absent, or immu-
noedited out, pathological diagnosis could be compromised. b) CUP metastasis may arise in a genetically favored 
tissue promoting growth of both primary cancers and metastases as predicted by the seed and soil paradigm. 
Importantly, scenarios a) and b) do not exclude each other and thus both of them could play a role in many cases 
of CUP.
Patients and Methods
Cancer cases were retrieved from the Swedish Cancer Registry and combined individually with population data-
bases at Center for Primary Health Care Research, Malmö, Lund University. These Swedish registers, provided 
by Statistics Sweden, included national census data (1960–1990) with information on individual’s socioeconomic 
status, the Swedish population register (1990–2012) and the Multigeneration Register, containing the popula-
tion in families, and constituting the Swedish Family-Cancer Database, used by us in numerous studies37. In the 
Database, the offspring generation was born after 1931 and the parental population was born any time earlier. 
In the current Database the offspring generation has reached age 80 years; siblings can be defined only in the 
offspring generation. All linkages were performed using the national ten-digit civic identification number that is 
assigned to each person in Sweden for his or her lifetime. This number was replaced by a serial number for each 
person in order to provide anonymity.
The Cancer Registry uses International Classification of Diseases (ICD) codes to identify malignant tumors. 
CUP was identified with ICD-7 code 199. In total we had 56,049 CUP patients, of which 26,689 (47.6%) had 
adenocarcinoma, 9444 (16.8%) undifferentiated carcinoma, 1801 (3.2%) melanoma and 2538 (4.5%) with squa-
mous cell cancer; the rest had miscellaneous or missing histology. ICD-9 codes, available from 1987 onwards, 
were used to identify the anatomic site where metastases were found. These included ‘unspecified CUP’ (ICD-9 
code 1990–1991, metastases often spread to multiple organs), ‘liver CUP’ with liver metastasis, ‘thorax CUP’ with 
lung involvement (including thorax and pleura), ‘abdominal CUP’ with abdominal metastases (including ovary) 
and ‘other CUP’ with other metastatic locations (any other specified site). A total of 33,677 patients were diag-
nosed with an ICD-9 code, including 7210 (21.4%) with metastases located in the thorax, 6064 (18.0%) located 
in the liver, 6414 (19.0%) located in the abdomen and 11,433 (33.9%) located in undefined and multiple sites; the 
remaining 8% were rare metastasis in the bone, brain and skin.
Family relationships were defined by mutually exclusive probands: parent only, sibling only, parent and sib-
ling, and any first degree relative. Cancer risks were calculated for offspring CUP by cancer in a proband, or in 
reverse order, for offspring cancer by CUP in a proband. Note that for parental probands the two ways of calcula-
tion are completely independent. Person-years were calculated from the offspring date of birth, depending on the 
family history, until diagnosis of cancer, death, emigration or closing date (December 31, 2012), whichever came 
first. Only the first diagnosed cancer was considered. Standardized incidence ratios (SIRs) were calculated as the 
ratio of observed to expected number of cases38. The expected numbers were calculated for all individuals without 
a history of a specific cancer, and the rates were standardized by 5-year-age, gender, period (5 years group), socio-
economic status and residential area39. The 95% confidence interval (95%CI) of the SIR was calculated assuming 
a Poisson distribution, and they were rounded to the nearest two decimals39. Associations are called only when 
95%CIs did not include 1.00. All analyses were performed using the SAS statistical package (version 9.1; SAS 
Institute, Cary, NC).
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines.
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